Table 1.
Quartile of mean glucose (% of patients) |
p-value | ||||
---|---|---|---|---|---|
Group 1 (n=52) | Group 2 (n=51) | Group 3 (n=51) | Group 4 (n=52) | ||
Age at diagnosis metastatic CRC (yr) | 0.038 | ||||
Mean±SD | 59.7±12.4 | 60.1±9.8 | 63.9±11.5 | 67.7±9.6 | |
Gender | 0.038 | ||||
Male | 61.5 | 78.4 | 56.9 | 76.9 | |
Female | 38.5 | 21.6 | 43.1 | 23.1 | |
ECOG performance status | 0.082 | ||||
0, 1 | 88.5 | 82.4 | 70.6 | 86.5 | |
≥ 2 | 11.5 | 17.6 | 29.4 | 13.5 | |
BMI (kg/m2) | 0.701 | ||||
< 25 | 76.9 | 70.6 | 66.7 | 73.1 | |
≥ 25 | 23.1 | 29.4 | 33.3 | 26.9 | |
Comorbidity conditions by CCI scale | 0.007 | ||||
0, 1 | 98.1 | 96.1 | 86.3 | 80.8 | |
≥ 2 | 1.9 | 3.9 | 13.7 | 19.2 | |
Diabetes mellitus | < 0.001 | ||||
Yes | 0 | 0 | 17.6 | 69.2 | |
No | 100 | 100 | 82.4 | 30.8 | |
Hypertension | 0.076 | ||||
Yes | 19.2 | 29.4 | 35.3 | 42.3 | |
No | 80.8 | 70.6 | 64.7 | 57.7 | |
Location of primary tumor | 0.382 | ||||
Colon | 50.0 | 45.1 | 58.8 | 59.6 | |
Rectum | 50.0 | 54.9 | 41.2 | 40.4 | |
Stage | 0.072 | ||||
M1a | 19.2 | 43.1 | 29.4 | 32.7 | |
M1b | 80.8 | 56.9 | 70.6 | 67.3 | |
No. of palliative chemotherapies | 0.598 | ||||
1 | 59.6 | 52.9 | 58.8 | 63.5 | |
2 | 21.2 | 33.3 | 29.4 | 28.8 | |
≥ 3 | 19.2 | 13.7 | 11.8 | 7.7 | |
Use of dexamethasone (mean±SD) | |||||
Dose (mg) | 278.4±317.1 | 224.9±263.7 | 246.9±284.7 | 249.5±234.4 | 0.808 |
Duration (days) | 22.0±21.8 | 23.1±25.8 | 25.1±28.6 | 28.9±43.5 | 0.689 |
Use of megestrol acetate (mean±SD) | |||||
Dose (g) | 0.43±1.17 | 0.40±0.94 | 0.66±1.16 | 0.71±1.58 | 0.468 |
Duration (days) | 17.0±28.5 | 25.4±49.9 | 33.0±54.8 | 39.0±78.1 | 0.213 |
CRC, colorectal cancer; SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; BMI, body mass index; CCI, Charlson Comorbidity Index; M1a, metastasis confined to one organ or site (e.g., liver, lung, ovary, or non-regional node); M1b, metastases in more than one organ/site or the peritoneum.